Zdravka Medarova has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Multifaceted Role of microRNA-10b (miR-10b) in Glioblastoma: From Oncogenic Driver to Therapeutic Target

    by Ming Chen, Zdravka Medarova, Lisa R. Rogers, Anna Moore

    Glioblastoma (GBM) remains one of the most lethal and treatment-resistant human malignancies, characterized by extreme molecular heterogeneity and a highly immunosuppressive tumor microenvironment (TME). MicroRNAs are a set of small endogenous non-coding RNA molecules which play critical roles in various biological processes including carcinogenesis. Recent evidence identifies microRNA-10b (miR-10b) as a regulator of gliomagenesis, with glioblastoma exhibiting a unique state of “oncogene addiction” to this molecule. This review summarizes current research on the mechanistic roles of miR-10b in GBM tumor progression and immune evasion, evaluates innovative antisense oligonucleotide delivery systems, and explores the clinical potential of combining miR-10b inhibition with standard-of-care treatments.


  • Open Access

    Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy

    by Subrata K. Ghosh, Douglas Lazarus, Neil Robertson, Qiyong P. Liu, Elizabeth Kenyon, Christian L. Mallett, Ming Chen, Zdravka Medarova, Anna Moore

    Purpose: Tumor-specific immunotherapies selectively target tumor cells with reduced toxicity compared to conventional treatments. Pattern recognition receptors, such as retinoic acid-inducible gene I (RIG-I)-like receptors, have been used to induce broad antitumor responses but their off-target effects and delivery issues hinder their clinical translation. To overcome these challenges, we present a strategy that involves the intracellular assembly of the RIG-I agonist on a tumor-specific RNA template (e.g., miRNA-21) by delivering a 5'-triphosphate single-stranded RNA RIG-I agonist (RIGA-miRNA-21) by a superparamagnetic nanoparticle carrier (TTX) to initiate specific RIG-I signaling and antitumor immune responses. Magnetic properties of TTX enable its detection by magnetic resonance imaging (MRI) supporting the concept of image-guided therapy. Procedures: A single-stranded anti-miR-21 5’-triphosphate RIG-I agonist was conjugated to the dextran coat of the nanoparticles through disulfide bonds producing TTX-RIGA-miR-21 and tested in vitro and in vivo in B16-F10 melanoma model. Delivery of the TTX carrier was demonstrated in mice bearing B16-F10 tumors by MRI. Therapeutic studies included intravenous injections of TTX-RIGA-miR-21 or controls for 7 days starting on Day 4 after tumor implantation. On Day 15, animals were rechallenged with additional B16-F10 cells implanted on the opposite side. Results: We demonstrated that TTX-RIGA-miR21 was able to induce miRNA-21-dependent RIG-I signaling and apoptosis in melanoma cells, inhibit tumor growth, and induce immunity against tumor rechallenge in an animal model. Conclusions: Our template-driven approach brings RIG-I closer to becoming a clinically relevant target in oncology by specifically activating immune responses within tumor cells through systemic RIG-I agonist delivery.

  • Open Access

    Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models

    by Bryan D. Kim, Ming Chen, Sujan K. Mondal, Elizabeth Kenyon, Christiane L. Mallett, Ana Decarvalho, Zdravka Medarova, Anna Moore

    Glioblastoma (GBM) is the most aggressive primary cancer with poor survival. In the absence of an effective treatment and a high probability of recurrence, new therapeutic approaches are urgently needed. This study focused on targeting microRNA-10b (miR-10b) highly expressed in GBM cells that has been identified as one of the key drivers of GBM progression. Inhibiting miR-10b using antisense oligonucleotides (ASOs) has shown promise, but its delivery is challenging due to short circulation half-life, degradation by nucleases, and limited blood–brain barrier (BBB) permeability. To overcome these barriers, we employed a magnetic nanoparticle (MN) platform to deliver anti-miR-10b ASOs (MN-anti-miR10b). In addition to serving as a delivery vehicle, these nanoparticles can be used for monitoring delivery using magnetic resonance imaging (MRI). In therapeutic studies in orthotopic models of GBM presented here we used MN-anti-miR10b as well as TTX-MC138, a clinically tested anti-miR10b nanotherapeutic now in Phase I trials in patients with solid (non-GBM) cancers. Both formulations showed efficient delivery, as demonstrated by imaging and improved survival, leading to target inhibition and increased apoptosis. This approach may offer a novel strategy for delivering therapeutics to GBM and improving patient outcomes in one of the most aggressive and treatment-resistant forms of brain cancer.


  • JoVE Video Dataset

    by Bryan D. Kim, Sujan K. Mondal, Elizabeth Kenyon, Ming Chen, Christiane L. Mallett, Ana C. Decarvalho, Zdravka Medarova, Anna Moore

    Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain malignancy for which there is no cure. The blood-brain barrier is a ...

  • Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

    by Bryan D. Kim, Sujan K. Mondal, Elizabeth Kenyon, Ming Chen, Christiane L. Mallett, Ana C. Decarvalho, Zdravka Medarova, Anna Moore

    Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain malignancy for which there is no cure. The blood-brain barrier is a ...


  • Open Access

    Template-Directed RIG-I Agonist Assembly for Targeted Cancer Immunotherapy

    by Subrata K. Ghosh, Neil Robertson, Edward Crosier, Michael Dudley, Qiyong P. Liu, Zdravka Medarova

    Recent developments in the use of pattern recognition receptors (PRRs) aim to harness the innate power of the immune system for cancer therapy. Understanding how to recruit PRRs, such as RIG-I, in a tumor-selective manner is critical for its adoption in the clinic. We describe the use of a tumor-selective template-based agonist of RIG-I to induce type-I IFN signaling and tumor cell apoptosis. The agonist, termed ss-ppp-miRNA-21, comprises a single stranded RNA oligonucleotide modified with a 5’-triphosphate and complementary to an endogenous miRNA enriched in tumor cells. We demonstrate the efficacy of the template-directed approach and detail mechanistic studies validating the hypothesis of a template-directed RIG-I agonist assembly using miRNA-21 as a target. The template-directed strategy described here moves us closer to making RIG-I a clinically relevant target in oncology because it achieves targeted activation of innate immunity in the tumor microenvironment in the context of systemic agonist injection.

  • Open Access

    Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine

    by Ellen S. Smith, Eric Whitty, Byunghee Yoo, Anna Moore, Lorenzo F. Sempere, Zdravka Medarova

    Traditional targeted therapeutic agents have relied on small synthetic molecules or large proteins, such as monoclonal antibodies. These agents leave a lot of therapeutic targets undruggable because of the lack or inaccessibility of active sites and/or pockets in their three-dimensional structure that can be chemically engaged. RNA presents an attractive, transformative opportunity to reach any genetic target with therapeutic intent. RNA therapeutic design is amenable to modularity and tunability and is based on a computational blueprint presented by the genetic code. Here, we will focus on short non-coding RNAs (sncRNAs) as a promising therapeutic modality because of their potency and versatility. We review recent progress towards clinical application of small interfering RNAs (siRNAs) for single-target therapy and microRNA (miRNA) activity modulators for multi-target therapy. siRNAs derive their potency from the fact that the underlying RNA interference (RNAi) mechanism is catalytic and reliant on post-transcriptional mRNA degradation. Therapeutic siRNAs can be designed against virtually any mRNA sequence in the transcriptome and specifically target a disease-causing mRNA variant. Two main classes of microRNA activity modulators exist to increase (miRNA mimics) or decrease (anti-miRNA inhibitors) the function of a specific microRNA. Since a single microRNA regulates the expression of multiple target genes, a miRNA activity modulator can have a more profound effect on global gene expression and protein output than siRNAs do. Both types of sncRNA-based drugs have been investigated in clinical trials and some siRNAs have already been granted FDA approval for the treatment of genetic, cardiometabolic, and infectious diseases. Here, we detail clinical results using siRNA and miRNA therapeutics and present an outlook for the potential of these sncRNAs in medicine.